We evaluated the efficacy of a GLP-1 analogue, liraglutide, using continuous glucose monitoring (CGM). The subjects included 13 patients with type 2 diabetes for which oral antidiabetic agents had been used. The daily mean blood glucose level, SD of the daily blood glucose level, duration of hyperglycemia (blood glucose > 180 mg/d/), mean amplitude of glycemic excursions (MAGE) and J-index were compared before and after treatment with liraglutide. The BMI, duration of diabetes, CPR index and postprandial CPR level were examined in relation to the recovery rate of the mean blood glucose level and the SD. The daily mean blood glucose level significantly improved from 151.0 mg/d/ to 121.0 mg/d/ (median, p = 0.002). The SD of the daily blood glucose level (43.0 mg/d/ to 14.0 mg/d/, p = 0.002), duration of hyperglycemia (23.0 % to 0.0 %, p = 0.002), MAGE (109.0 mg/d/ to 33.0 mg/d/, p = 0.001) and J-index (36.9 to 18.5, p = 0.002) significantly improved. A significantly negative correlation was observed between the recovery rate of the SD and the duration of diabetes. Liraglutide improves the average blood glucose level and also has a positive effect on flattening the blood glucose levels.
|Number of pages||6|
|Journal||Journal of the Japan Diabetes Society|
|Publication status||Published - Jul 1 2013|
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism